Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Endocrine Disorders
Published in: BMC Endocrine Disorders 1/2024

Open Access 01-12-2024 | Diabetes | Research

Effects of conditioned media derived from human Wharton’s jelly mesenchymal stem cells on diabetic nephropathy and hepatopathy via modulating TGF-β and apelin signaling pathways in male rats

Authors: Zeinab Karimi, Gholamreza Daryabor, Fatemeh Masjedi

Published in: BMC Endocrine Disorders | Issue 1/2024

Login to get access

Abstract

Background

Diabetic nephropathy and hepatopathy are health problems described by specific renal and hepatic structure and function disturbances. The protective effects of the stem cell secretome have been shown in several kidney and liver diseases. The current study aims to evaluate the capability of conditioned media derived from human Wharton’s jelly mesenchymal stem cells (hWJ-MSCs-CM) to alleviate diabetic complications.

Methods

Twenty Sprague Dawley rats were made diabetic through injection of STZ (60 mg/kg, i.p.). At week 8, diabetic rats were divided into two groups: treated [DM + hWJ-MSCs-CM (500 µl/rat for three weeks, i.p.)] and not treated (DM). At the 11th week, three groups (control, DM, and DM + hWJ-MSCs-CM) were kept in metabolic cages, and urine was collected for 24 h. The serum samples were maintained for measuring fasting blood glucose (FBG) and kidney and liver functional analysis. The left kidney and liver parts were kept at -80 °C to assess apelin and transforming growth factor-beta (TGF-β) expression. The right kidney, pancreas, and liver parts were used for histopathologic evaluation.

Results

DM was detected by higher FBG, microalbuminuria, increased albumin/creatinine ratio, and pancreas, renal, and hepatic structural disturbances. Diabetic hepatopathy was determined by increasing liver enzymes and decreasing total bilirubin. The TGF-β gene expression was significantly upregulated in the diabetic kidney and liver tissues. Apelin gene expression was significantly downregulated in the diabetic liver tissue but did not change in kidney tissue. Administration of hWJ-MSCs-CM improved renal and hepatic functional and structural disturbances. Moreover, CM therapy significantly decreased TGF-β expression and enhanced apelin expression in the kidney and liver tissues.

Conclusion

Human WJ-MSCs-CM may have protective effects on diabetic renal and hepatic complications. These effects may happen through the regulation of TGF-β and apelin signaling pathways.
Literature
1.
Masjedi F, Gol A, Dabiri S. Preventive effect of Garlic (Allium sativum L.) on serum biochemical factors and histopathology of Pancreas and Liver in Streptozotocin- Induced Diabetic rats. Iran J Pharm Res. 2013;12(3):325–38.PubMedPubMedCentral
2.
Abolfathi AA, Mohajeri D, Rezaie A, Nazeri M. Protective effects of Green Tea extract against Hepatic Tissue Injury in Streptozotocin-Induced Diabetic rats. Evid Based Complement Alternat Med. 2012;2012:740671.PubMedPubMedCentralCrossRef
3.
de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 Diabetes. The Verona Diabetes Study. Diabetes Care. 1999;22(5):756–61.PubMedCrossRef
4.
Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of Liver Disease in type 2 Diabetes and management of patients with Diabetes and Liver Disease. Diabetes Care. 2007;30(3):734–43.PubMedCrossRef
5.
Athyros VG, Mikhailidis DP, Didangelos TP, Giouleme OI, Liberopoulos EN, Karagiannis A, Kakafika AI, Tziomalos K, Burroughs AK, Elisaf MS. Effect of multifactorial treatment on non-alcoholic fatty Liver Disease in metabolic syndrome: a randomised study. Curr Med Res Opin. 2006;22(5):873–83.PubMedCrossRef
6.
Brown KL, Darris C, Rose KL, Sanchez OA, Madu H, Avance J, Brooks N, Zhang MZ, Fogo A, Harris R, et al. Hypohalous acids contribute to renal extracellular matrix damage in experimental Diabetes. Diabetes. 2015;64(6):2242–53.PubMedPubMedCentralCrossRef
7.
Forbes JM, Cooper ME, Oldfield MD, Thomas MC. Role of advanced glycation end products in diabetic Nephropathy. J Am Soc Nephrology: JASN. 2003;14(8 Suppl 3):254–8.CrossRef
8.
Mirani M, Bahmanpour S, Masjedi F, Derakhshan Z, Dara M, Nasr-Esfahani MH, Tabei SMB. Pyridoxamine protects human granulosa cells against advanced glycation end-products-induced steroidogenesis disturbances. Mol Biol Rep. 2023;50(10):8537–49.PubMedCrossRef
9.
Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, García-Pérez J. Inflammatory molecules and pathways in the pathogenesis of diabetic Nephropathy. Nat Rev Nephrol. 2011;7(6):327–40.PubMedCrossRef
10.
Jakuš V, Sapák M, Kostolanská J. Circulating TGF-β1, glycation, and oxidation in children with Diabetes Mellitus type 1. Exp Diabetes Res. 2012;2012:510902.PubMedPubMedCentralCrossRef
11.
Wang L, Wang HL, Liu TT, Lan HY. TGF-Beta as a Master Regulator of Diabetic Nephropathy. Int J Mol Sci 2021;22(15).
12.
Ibrahim S, Rashed L. Estimation of transforming growth factor-beta 1 as a marker of renal injury in type II Diabetes Mellitus. Saudi Med J. 2007;28(4):519–23.PubMed
13.
Shaker YM, Soliman HA, Ezzat E, Hussein NS, Ashour E, Donia A, Eweida SM. Serum and urinary transforming growth factor beta 1 as biochemical markers in diabetic Nephropathy patients. Beni-Suef Univ J Basic Appl Sci. 2014;3(1):16–23.
14.
Chen H, Liu C, Cheng C, Zheng L, Huang K. Effects of Apelin peptides on Diabetic Complications. Curr Protein Pept Sci. 2018;19(2):179–89.PubMed
15.
Kadoglou NP, Tsanikidis H, Kapelouzou A, Vrabas I, Vitta I, Karayannacos PE, Liapis CD, Sailer N. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 Diabetes Mellitus. Metabolism. 2010;59(3):373–9.PubMedCrossRef
16.
Kursunluoglu-Akcilar R, Kilic-Toprak E, Kilic-Erkek O, Turgut S, Bor-Kucukatay M. Apelin-induced hemorheological alterations in DOCA-salt hypertensive rats. Clin Hemorheol Microcirc. 2014;56(1):75–82.PubMedCrossRef
17.
Janfeshan S, Masjedi F, Karimi Z. Protective effects of limb remote ischemic per-conditioning on the heart injury induced by renal ischemic-reperfusion through the interaction of the apelin with the RAS/iNOS pathway. Bioimpacts. 2024;14(2):27567–7.
18.
Ringström C, Nitert MD, Bennet H, Fex M, Valet P, Rehfeld JF, Friis-Hansen L, Wierup N. Apelin is a novel islet peptide. Regul Pept. 2010;162(1–3):44–51.PubMedCrossRef
19.
Han S, Englander EW, Gomez GA, Rastellini C, Quertermous T, Kundu RK, Greeley GH Jr. Pancreatic islet APJ deletion reduces islet density and glucose tolerance in mice. Endocrinology. 2015;156(7):2451–60.PubMedCrossRef
20.
Day RT, Cavaglieri RC, Feliers D. Apelin retards the progression of diabetic Nephropathy. Am J Physiol Renal Physiol. 2013;304(6):F788–800.PubMedCrossRef
21.
Chen H, Li J, Jiao L, Petersen RB, Li J, Peng A, Zheng L, Huang K. Apelin inhibits the development of diabetic Nephropathy by regulating histone acetylation in Akita mouse. J Physiol. 2014;592(3):505–21.PubMedCrossRef
22.
Gao Z, Zhong X, Tan YX, Liu D. Apelin–13 alleviates diabetic Nephropathy by enhancing nitric oxide production and suppressing kidney tissue fibrosis. Int J Mol Med 2021;48(3).
23.
Chen H, Wan D, Wang L, Peng A, Xiao H, Petersen RB, Liu C, Zheng L, Huang K. Apelin protects against acute renal injury by inhibiting TGF-β1. Biochim Biophys Acta. 2015;1852(7):1278–87.PubMedCrossRef
24.
Owen NE, Nyimanu D, Kuc RE, Upton PD, Morrell NW, Alexander GJ, Maguire JJ, Davenport AP. Plasma levels of apelin are reduced in patients with liver fibrosis and Cirrhosis but are not correlated with circulating levels of bone morphogenetic protein 9 and 10. Peptides. 2021;136:170440.PubMedPubMedCentralCrossRef
25.
Nooshabadi VT, Mardpour S, Yousefi-Ahmadipour A, Allahverdi A, Izadpanah M, Daneshimehr F, Ai J, Banafshe HR, Ebrahimi-Barough S. The extracellular vesicles-derived from mesenchymal stromal cells: a new therapeutic option in regenerative medicine. J Cell Biochem. 2018;119(10):8048–73.PubMedCrossRef
26.
Mohammadi-Mahdiabadi-Hasani MH, Nabiuni M, Parivar K, Yari S, Sahebi AR, Miyan J. The effects of embryonic cerebrospinal fluid on the viability and neuronal differentiation of adipose tissue-derived stem cells in Wistar rats. Cell J. 2020;22(2):245–52.PubMed
27.
Sanie-Jahromi F, Nowroozzadeh MH, Khodabandeh Z, Soheili Z-S, Khajehahmadi Z, Emadi Z, Talebnejad MR. Effects of the secretome of human Wharton’s jelly mesenchymal stem cells on the proliferation and apoptosis gene expression of the retinal pigmented epithelium. Exp Eye Res. 2021;205:108528.PubMedCrossRef
28.
Arno AI, Amini-Nik S, Blit PH, Al-Shehab M, Belo C, Herer E, Tien CH, Jeschke MG. Human Wharton’s jelly mesenchymal stem cells promote skin wound healing through paracrine signaling. Stem Cell Res Ther. 2014;5(1):28.PubMedPubMedCentralCrossRef
29.
Fong CY, Tam K, Cheyyatraivendran S, Gan SU, Gauthaman K, Armugam A, Jeyaseelan K, Choolani M, Biswas A, Bongso A. Human Wharton’s jelly stem cells and its conditioned medium enhance healing of excisional and diabetic wounds. J Cell Biochem. 2014;115(2):290–302.PubMedCrossRef
30.
Liu B, Ding F, Hu D, Zhou Y, Long C, Shen L, Zhang Y, Zhang D, Wei GJSCR. Therapy: human umbilical cord mesenchymal stem cell conditioned medium attenuates renal fibrosis by reducing inflammation and epithelial-to-mesenchymal transition via the TLR4/NF-κB signaling pathway in vivo and in vitro. 2018;9(1):1–14.
31.
Xiang E, Han B, Zhang Q, Rao W, Wang Z, Chang C, Zhang Y, Tu C, Li C, Wu D. Human umbilical cord-derived mesenchymal stem cells prevent the progression of early diabetic Nephropathy through inhibiting inflammation and fibrosis. Stem Cell Res Ther. 2020;11(1):336.PubMedPubMedCentralCrossRef
32.
Chen L, Zhang J, Yang L, Zhang G, Wang Y, Zhang S. The effects of conditioned medium derived from mesenchymal stem cells cocultured with hepatocytes on damaged hepatocytes and Acute Liver Failure in rats. Stem Cells Int. 2018;2018:9156560.PubMedPubMedCentralCrossRef
33.
Muto H, Ito T, Tanaka T, Yokoyama S, Yamamoto K, Imai N, Ishizu Y, Maeda K, Honda T, Ishikawa T, et al. Conditioned medium from stem cells derived from human exfoliated deciduous teeth ameliorates NASH via the gut-liver axis. Sci Rep. 2021;11(1):18778.PubMedPubMedCentralCrossRef
34.
Khodabandeh Z, Rezaeian L, Edalatmanesh MA, Mogheiseh A, Tanideh N, Dianatpour M, Zare S, Bordbar H, Baghban N, Tamadon A. Stereological evaluation of rabbit Fetus Liver after Xenotransplantation of Human Wharton’s jelly-derived mesenchymal stromal cells. Int J Organ Transplantation Med. 2022;13(1):15–24.
35.
Varaa N, Azandeh S, Khodabandeh Z, Gharravi AM. Wharton’s Jelly Mesenchymal Stem cell: various protocols for isolation and differentiation of hepatocyte-like cells; Narrative Review. Iran J Med Sci. 2019;44(6):437–48.PubMed
36.
Talaei-Khozani T, Khodabandeh Z, Jaberipour M, Hosseini A, Bahmanpour S, Vojdani Z. Comparison of hepatic nuclear factor-4 expression in two- and three-dimensional culture of Wharton’s jelly-derived cells exposed to hepatogenic medium. Rom J Morphol Embryol. 2015;56(4):1365–70.PubMed
37.
Bai Y, Wang J, He Z, Yang M, Li L, Jiang H. Mesenchymal stem cells Reverse Diabetic Nephropathy Disease via Lipoxin A4 by targeting transforming growth factor β (TGF-β)/smad pathway and pro-inflammatory cytokines. Med Sci Monit. 2019;25:3069–76.PubMedPubMedCentralCrossRef
38.
Furman BL. Streptozotocin-Induced Diabetic models in mice and rats. Curr Protocols. 2021;1(4):e78.CrossRef
39.
Hashemi SM, Hassan ZM, Hossein-Khannazer N, Pourfathollah AA, Soudi S. Investigating the route of administration and efficacy of adipose tissue-derived mesenchymal stem cells and conditioned medium in type 1 diabetic mice. Inflammopharmacology. 2020;28(2):585–601.PubMedCrossRef
40.
Kaur M, Bedi O, Sachdeva S, Reddy BV, Kumar P. Rodent animal models: from mild to advanced stages of diabetic Nephropathy. Inflammopharmacology. 2014;22(5):279–93.PubMedPubMedCentralCrossRef
41.
Levin A, Stevens PE, Bilous RW, Coresh J, De Francisco AL, De Jong PE, Griffith KE, Hemmelgarn BR, Iseki K, Lamb EJ. Kidney Disease: improving global outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic Kidney Disease. Kidney Int Supplements. 2013;3(1):1–150.
42.
Masjedi F, Gol A, Dabiri S, Javadi A. Investigating the Preventive Effect of Garlic on blood glucose levels and histopathology of pancreas in streptozotocin-induced Diabetic rats. Physiol Pharmacol. 2009;13(2):179–90.
43.
Forghani N, Karimi Z, Mokhtari M, Shariati M, Masjedi F. Association of Oxidative Stress with Kidney Injury in a hyperandrogenemic female rat model. Iran J Med Sci. 2023;48(2):187–97.PubMedPubMedCentral
44.
Pakfetrat Z, Janfeshan S, Masjedi F, Rafiei M, Karimi Z. Involvement of oxidative stress and toll-like receptor-4 signaling pathways in gentamicin-induced nephrotoxicity in male Sprague Dawley rats. Drug Chem Toxicol. 2022;45(6):2568–75.PubMedCrossRef
45.
Thoolen B, Maronpot RR, Harada T, Nyska A, Rousseaux C, Nolte T, Malarkey DE, Kaufmann W, Küttler K, Deschl U, et al. Proliferative and nonproliferative lesions of the rat and mouse hepatobiliary system. Toxicol Pathol. 2010;38(7 Suppl):5s–81s.PubMedCrossRef
46.
Masjedi F, Gol A, Dabiri S, Javadi A. Preventive effect of garlic on histopathology of liver and markers of hepatic Injury in Streptozotocin-Induced Diabetic rats. Iran J Endocrinol Metabolism. 2009;11(4):433–41.
47.
Gholizadeh-Ghaleh Aziz S, Naderi R, Mahmodian N. Ameliorative effects of tropisetron on liver injury in streptozotocin-induced diabetic rats. Arch Physiol Biochem. 2021;127(4):367–72.PubMedCrossRef
48.
Tesch GH, Allen TJ. Rodent models of streptozotocin-induced diabetic Nephropathy (methods in Renal Research). 2007;12(3):261–6.
49.
Adewole SO, Caxton-Martins EA, Ojewole JA. Protective effect of quercetin on the morphology of pancreatic beta-cells of streptozotocin-treated diabetic rats. Afr J Traditional Complement Altern Medicines: AJTCAM. 2006;4(1):64–74.PubMedCentral
50.
Singh A, Bodakhe SH. Biochemical evidence indicates the Preventive Effect of Resveratrol and Nicotinamide in the treatment of STZ-induced Diabetic Cataract. Curr Eye Res. 2021;46(1):52–63.PubMedCrossRef
51.
Refardt J. Diagnosis and differential diagnosis of Diabetes insipidus: update. Best Pract Res Clin Endocrinol Metab. 2020;34(5):101398.PubMedCrossRef
52.
Masjedi F, Gol A, Dabiri S. Preventive Effect of Garlic Juice on Food Intake and Serum Levels of Glucose, cholesterol and triglycerides in streptozotocin-induced Diabetic rats. J Med Plants. 2010;9(36):124–35.
53.
Zheng C, Huang L, Luo W, Yu W, Hu X, Guan X, Cai Y, Zou C, Yin H, Xu Z, et al. Inhibition of STAT3 in tubular epithelial cells prevents kidney fibrosis and Nephropathy in STZ-induced diabetic mice. Cell Death Dis. 2019;10(11):848.PubMedPubMedCentralCrossRef
54.
55.
Yuan Y, Shi M, Li L, Liu J, Chen B, Chen Y, An X, Liu S, Luo R, Long D, et al. Mesenchymal stem cell-conditioned media ameliorate diabetic endothelial dysfunction by improving mitochondrial bioenergetics via the Sirt1/AMPK/PGC-1α pathway. Clin Sci. 2016;130(23):2181–98.CrossRef
56.
57.
Stehouwer CDA, Smulders YM. Microalbuminuria and Risk for Cardiovascular Disease. Anal Potential Mech. 2006;17(8):2106–11.
58.
Price DA, Porter LE, Fisher Gordonm, De’oliveira JMF NDL, Laffel LMB, Passan DR. Williams GH, Hollenberg NK: the Paradox of the low-renin state in Diabetic Nephropathy. 1999;10(11):2382–91.
59.
Wan Y, Garner J, Wu N, Phillip L, Han Y, McDaniel K, Annable T, Zhou T, Francis H, Glaser S, et al. Role of stem cells during diabetic liver injury. J Cell Mol Med. 2016;20(2):195–203.PubMedCrossRef
60.
Whitehead MW, Hawkes ND, Hainsworth I, Kingham JG. A prospective study of the causes of notably raised aspartate aminotransferase of liver origin. Gut. 1999;45(1):129–33.PubMedPubMedCentralCrossRef
61.
Zeng F, Luo J, Han H, Xie W, Wang L, Han R, Chen H, Cai Y, Huang H, Xia Z. Allopurinol ameliorates liver injury in type 1 diabetic rats through activating Nrf2. Int J ImmunoPathol Pharmacol. 2021;35:20587384211031417.PubMedPubMedCentralCrossRef
62.
Ozkan S, Isildar B, Ercin M, Gezginci-Oktayoglu S, Konukoglu D, Neşetoğlu N, Oncul M, Koyuturk M. Therapeutic potential of conditioned medium obtained from deferoxamine preconditioned umbilical cord mesenchymal stem cells on diabetic Nephropathy model. Stem Cell Res Ther. 2022;13(1):438.PubMedPubMedCentralCrossRef
63.
Hu H, He L, Li L, Chen L. Apelin/APJ system as a therapeutic target in Diabetes and its Complications. Mol Genet Metab. 2016;119(1–2):20–7.PubMedCrossRef
64.
Zhao B, Li S, Guo Z, Chen Z, Zhang X, Xu C, Chen J, Wei C. Dopamine receptor D2 inhibition alleviates diabetic hepatic stellate cells fibrosis by regulating the TGF-β1/Smads and NFκB pathways. Clin Exp Pharmacol Physiol. 2021;48(3):370–80.PubMedCrossRef
65.
Gao LR, Zhang NK, Zhang Y, Chen Y, Wang L, Zhu Y, Tang HH. Correction to: overexpression of apelin in Wharton’ jelly mesenchymal stem cell reverses insulin resistance and promotes pancreatic β cell proliferation in type 2 diabetic rats. Stem Cell Res Ther. 2019;10(1):6.PubMedPubMedCentralCrossRef
Metadata
Title
Effects of conditioned media derived from human Wharton’s jelly mesenchymal stem cells on diabetic nephropathy and hepatopathy via modulating TGF-β and apelin signaling pathways in male rats
Authors
Zeinab Karimi
Gholamreza Daryabor
Fatemeh Masjedi
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2024
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-023-01535-8

Other articles of this Issue 1/2024

BMC Endocrine Disorders 1/2024 Go to the issue

Research

Obesity and metabolic syndrome in patients with heart failure with preserved ejection fraction: a cross-sectional analysis of the Veradigm Cardiology Registry

Research

The prevalence of thyroid disorders in COVID-19 patients: a systematic review and meta-analysis

Research

Prediabetes remission after bariatric surgery: a 4-years follow-up study

Research

Therapeutic plasma exchange decreases serum triglyceride level rapidly and reduces early recurrence rate but no advantages in improving outcomes for patients with hyperlipidemic acute pancreatitis: a retrospective propensity score matching analysis based on twenty year’s experience

Research

Non-alcoholic fatty liver disease and gestational diabetes mellitus: a bidirectional two-sample mendelian randomization study

Research

Skin advanced glycation end-products as indicators of the metabolic profile in diabetes mellitus: correlations with glycemic control, liver phenotypes and metabolic biomarkers
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits